ClinicalTrials.gg

Program

BAT4406F

A development code. Also written as “BAT4406F Injection”.

Its studies are mostly in Nephrosis, Lipoid · Neuromyelitis Optica, led by Bio-Thera Solutions.

Furthest: phase 3, since Mar 24, 20263 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bio-Thera Solutions32 open or runningphase 3since Mar 24, 2026Sep 26, 2019Dec 31, 2027phase 2 · NCT06044350

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2019First study: phase 1 study in Neuromyelitis OpticaFirst studyNCT04146285 · 15 enrolled · China
  2. Jul 31, 2023Phase 2 study in Optic Neuromyelitis Spectrum DiseaseNCT06044350 · 162 enrolled · China
  3. Mar 24, 2026Phase 3 study in Nephrosis, LipoidPhase 3 reachedNCT07499700 · 192 planned · China
  4. Oct 2, 2026Primary completion moved from 2026-05-31 to 2027-12-31Date moved laterphase 2 · +19 months · NCT06044350

Ahead

  1. Dec 31, 2027Primary completion: phase 2 study in Optic Neuromyelitis Spectrum DiseaseNCT06044350
  2. Oct 26, 2030Primary completion: phase 3 study in Nephrosis, LipoidNCT07499700

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07499700Nephrosis, Lipoid · China3RecruitingOct 26, 2030192
NCT06044350Optic Neuromyelitis Spectrum Disease · China2Active, not recruitingDec 31, 2027162
NCT04146285Neuromyelitis Optica · China1CompletedMar 13, 202315

How it is read

Names in the registry

  • “BAT4406F”, 2 entries
  • “BAT4406F Injection”, 1 entry

Codes read as this program: BAT4406F.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.